The company is planning a “broad Phase 3 program” for two anticoagulants after they outperformed marketed medicines in a pair ...
Novo shares lost nearly a fifth of their value after an experimental combination treatment called cagrisema fell short of the ...
Mixed results from a study focused on lower back pain left analysts wanting as well as confused about Vertex's plans to forge ...
An startup formed by KdT Ventures intends to test the drug, which was once licensed to Merck and evaluated in multiple ...
The clearance of Tryngolza gives Ionis its first wholly-owned, marketed medicine. Elsewhere, Robert Temple became the latest ...
While the pharma is still developing a MorphoSys drug acquired in its $2.9 billion deal for the biotech, it is closing down sites in the U.S. and Germany.
Dec. 21, 2024 – Dec. 31, 2024 • New York, NY, USA, New York ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback